Ocular Therapeutix (OCUL) shares rose more than 12% in recent trading on Wednesday after the company said it will close enrollment this week in its registration trial evaluating Axpaxli for wet age-related macular degeneration.
Ocular said it expects to meet its target of randomizing at least 555 subjects in the trial, with participants enrolled across approximately 100 sites in the US, Argentina, India, and Australia.
The SOL-R trial is evaluating the safety and efficacy of Axpaxli dosed every six months versus aflibercept given every eight weeks, Ocular said.
The company said it plans to file a new drug application with the US Food and Drug Administration pending positive results from SOL-R and a separate registrational study, SOL-1.
Price: 7.80, Change: +0.86, Percent Change: +12.39
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。